Compounded GLP-1s have given rise to a cottage industry offering cheaper weight loss medications to many Americans — but now ...
After years of weight loss drug shortages, the FDA is saying there’s now an adequate supply for most medications and they ...
Compounding pharmacies will have to stop producing copycats of tirzepatide, the active ingredient in the blockbuster weight ...
AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.
1d
To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...
Compounded versions of popular drugs used for weight loss including Wegovy and Zepbound will soon no longer be available ...
Novo Nordisk announced a direct-to-consumer program that allows patients to buy Wegovy out of pocket at a lower cost.
Four-star-rated analyst Daniel Grosslight at Citi reiterated his Sell rating on Hims & Hers Health (HIMS) stock yesterday, ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
A federal judge’s ruling restricts compounding pharmacies from producing generic Zepbound, sparking concerns over affordability ...
How weight loss drugs actually work, and how big-name prescriptions differ from each other. What investors need to know about ...
Eli Lilly plans to launch Mounjaro, its blockbuster diabetes drug, in countries like China, India, Brazil and Mexico by 2026, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback